SYK: FY25 Deep Dive
FY25 revenue $25.12B (+11.2%) — first time crossing $25B. Organic sales growth 10.3% FY25 (Q4 +11%). Mako installed base 3,000+ worldwide; 2M+ robotic procedures cumulative. Net income $3.25B (+9%); Diluted EPS $8.40. FCF $4.28B (+23%). Q1-Q2 FY26 PT cuts swept post-Feb earnings: Goldman -$46, Citi -$35, Evercore -$35.
Key Takeaways
Stryker closed fiscal 2025 (calendar year ended December 31, 2025) at $25.12 billion of revenue, up 11.2% YoY — the first time the company crossed $25 billion. Organic sales growth was 10.3% for the full year (Q4 +11.0%), an exceptional pace for a $25B+ medical device franchise. Operating income was $4.89 billion (19.5% operating margin); net income $3.25 billion (+9%, $8.40 diluted EPS, +8%). The growth composition was heavily MedSurg + Neurotechnology-led: Q4 organic growth in that segment was +12.6% (vs Orthopedics +8.4%). The full-year US organic growth was 11.2% with international 7.5%. Mako (robotic-assisted surgery) had a record installation quarter Q4 with installed base now 3,000+ worldwide; cumulative robotic procedures crossed 2 million during 2025. Adjusted EPS $13.63 (+11.8%). Inari Medical (peripheral vascular acquisition) integration progressing — high-teens organic growth. Free cash flow was $4.28 billion (+23% from $3.49B FY24); capex $761M; dividends $1.28B. No buybacks in FY25 (vs $195M FY24, $155M FY23). Total debt $14.86B. Sell-side coverage is 8 analysts: 5 Buy / 3 Hold / 0 Sell, consensus PT $391, range $357-$454. Notable: Feb-April 2026 saw 7 of 8 covered actions trim PTs — Goldman $403→$357 (-$46), Citi $420→$385 (-$35), Evercore $400→$365 (-$35). The PT cuts reflect tariff-on-medical-devices concerns + valuation reset on tougher FY26 comp.
Main business structure
Stryker reports two operating segments:
| Segment | Approx FY25 Share | Q4 FY25 Organic Growth |
|---|---|---|
| MedSurg and Neurotechnology | ~58% | +12.6% |
| Orthopaedics | ~42% | +8.4% |
| Total | 100% | +11.0% |
MedSurg and Neurotechnology (~58%)
The fastest-growing major segment in mega-cap med devices. Sub-line Q4 FY25 organic growth detail (US):
| Sub-line | Q4 FY25 Organic Growth |
|---|---|
| Instruments (power tools) | +19.1% |
| Endoscopy (sustainability + sports medicine) | +11.1% |
| Medical (35, Procuity, Oceara, Sage products) | +13.6% |
| Vascular (incl Inari hemorrhagic) | +4.3% |
| Neurocranial | +9.9% |
The MedSurg + Neurotech segment combines surgical instruments, hospital beds + acute care equipment, endoscopy, and neurovascular devices. The +12.6% Q4 organic growth is the cleanest signal of capital equipment + consumables compounding in healthcare.
Inari Medical (closed 2024): peripheral vascular thrombectomy devices. Q3 FY25 commentary: "high teens pro forma organic" growth. Integration progressing per management.
Orthopaedics (~42%)
Joint replacement + trauma + extremities. Q4 FY25 sub-line detail:
| Sub-line | Q4 FY25 Organic Growth |
|---|---|
| US Knee | +7.6% |
| US Hips | +5.6% |
| US Trauma + Extremities | +8.5% |
| US Other ortho | +28.7% |
| International orthopaedics | +5.4% |
Mako robotic-assisted surgery is the structural moat: 3,000+ installed base globally (+record quarter Q4); 2M+ cumulative robotic procedures. Mako Spine, Mako Shoulder, Pangea plating system launches successful in FY25. The Mako economics: each robot drives recurring sales of disposables (single-use instruments, implants pulled into Mako-compatible products) — the razor-and-blade economics of the franchise.
Inari peripheral vascular segment crosses into MedSurg + Neuro Vascular reporting; for the FY25 organic-growth story it's a significant contributor.
Geographic mix. US ~75%, International ~25%. US-heavy — reflects high-priced specialty medical device pricing.
Customer concentration. Hospitals + ambulatory surgery centers (ASCs) globally. Highly fragmented; no single 10%+ customer.
Scale anchors. ~58,000 employees globally. R&D spend ~7-8% of revenue. ~30,000 SKUs; presence in 100+ countries.
Key core metrics (3-year trend)
1. Revenue and organic growth
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Revenue ($B) | 20.50 | 22.60 | 25.12 |
| YoY | — | +10% | +11% |
| Organic growth | — | +10.2% | +10.3% |
Two consecutive years of 10%+ organic growth on $20B+ base — the cleanest sustained organic growth profile in mega-cap med devices.
2. Mako + robotic surgery moat
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Cumulative robotic procedures | <1M | ~1.7M | 2M+ |
| Mako installed base | ~1,800 | ~2,400 | 3,000+ |
3. Operating margin
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| Operating income ($B) | 4.28 | 5.06 | 4.89 |
| Operating margin | 20.9% | 22.4% | 19.5% |
Operating margin compressed in FY25 — partly Inari integration costs, partly tariff impact, partly the structural mix shift (Inari segment lower-margin than legacy Stryker products). Adjusted operating margin (the company's preferred metric) expanded YoY for the second consecutive year.
4. Free cash flow + capital allocation
| FY23 | FY24 | FY25 | |
|---|---|---|---|
| OCF ($B) | 3.71 | 4.24 | 5.04 |
| Capex ($M) | 575 | 755 | 761 |
| FCF ($B) | 3.14 | 3.49 | 4.28 |
| Dividends ($M) | 1,139 | 1,219 | 1,284 |
| Buybacks ($M) | 155 | 195 | 0 |
FCF grew 23% to $4.28B. Buybacks were paused in FY25 (vs $195M FY24, $155M FY23) — reflecting Inari acquisition + ongoing M&A program priority. Total debt $14.86B (+$0.7B for Inari).
Market evaluation
Sell-side coverage (as of April 27, 2026). 8 analysts cover the stock.
| Rating | Count |
|---|---|
| Buy / Outperform / Overweight | 5 |
| Hold / Neutral | 3 |
| Sell | 0 |
Price targets. Consensus $391, range $357 (low: Goldman Sachs, Neutral) to $454 (high).
Recent analyst activity (Feb-April 2026). 8 covered actions in window — 7 of 8 were PT cuts:
- Goldman Sachs: $403 → $357 on April 9 — -$46, the largest cut, Neutral maintained, Street-low
- Citigroup: $420 → $385 on April 7 — -$35, Buy maintained
- Evercore ISI: $400 → $365 on April 6 — -$35, OP maintained
- UBS: two actions — $386 → $400 (Feb 24) → $380 (March 17) — Neutral, mild trim
- Truist: $395 → $380 on April 15 — Hold maintained
- Leerink Partners: initiated Outperform at $410 on April 13
- BTIG: reiterated Buy $397 on April 14
- Goldman + others trim cycle
The PT-cut wave reflects: (1) tariff-on-medical-devices uncertainty (potential 10-25% tariffs on EU + Asia-imported med device components); (2) tougher FY26 comp on +10.3% organic FY25 base; (3) Inari integration cost concerns. The 5 Buy ratings remain on the Mako + organic growth thesis.
Buy-side positioning. SYK is a core mega-cap med device holding paired with MDT, JNJ, ABT, BSX. Trades at premium multiple to peers on Mako + organic growth profile. Short interest below 1% of float.
FY25 corporate structure: organic growth compounder + tariff overhang
FY25 confirmed Stryker as the cleanest mega-cap medical device organic growth franchise: 10.3% organic growth on $25B base, Q4 +11.0%, MedSurg + Neuro at +12.6%, Mako installed base 3,000+ globally, 2M+ cumulative robotic procedures. The structural read is that the Mako razor-and-blade economics + Inari peripheral vascular addition + continued organic growth across MedSurg sub-lines combine for a durable mid-to-high-single-digit organic growth template through FY26-FY27. The Feb-April 2026 PT-cut cycle (7 of 8 actions PT cuts, Goldman -$46 the largest) is the bears' counter-thesis: tariff exposure on imported components, tougher comparison base, and Inari integration cost overhang. The Q1 FY26 earnings print this week is the proximate event for measuring continued organic growth pace + Mako installation cadence + tariff impact commentary + Inari integration progression.